Abstract:Background: Limited access to essential medicines is a global problem. Improving availability and affordability of essential medicines is a key objective of the National Essential Medicine Policy (NEMP) in China. In its initial implementation in 2009, the NEMP targeted primary hospitals with policies designed to increase availability of essential medicines and reduce patients' economic burden from purchasing medicines. We assessed medicine availability and price during the early years of the health reform in Shaanxi Province in underdeveloped western China. Methods: We undertook two public (hospitals) and private (pharmacy) sector surveys of prices and availability of medicines, in September, 2010 and April, 2012, by a standard methodology developed by WHO and Health Action International. We measured medicine availability in outlets at the time of the surveys and inflation-adjusted median unit prices (MUPs), taking 2010 as the base year. We used general estimating equations to calculate the significance of differences in availability from 2010 to 2012 and the Wilcoxon signed rank test to calculate the significance of differences in adjusted median prices. Findings: We collected data from 50 public sector hospitals and 36 private sector retail pharmacies in 2010 and 72 public hospitals and 72 retail pharmacies in 2012. Mean availability of surveyed medicines was low in both the public and private sectors; availability of many essential medicines decreased from 2010 to 2012, particularly in primary hospitals (from 27·4% to 22·3% for lowest priced generics; p<0·0001). The MUPs of originator brands and their generic equivalents decreased significantly from 2010 to 2012 in primary hospitals in comparison with secondary and tertiary hospitals. In the public sector, the median adjusted patient price was significantly lower in 2012 than in 2010 for 16 originator brands (difference −11·7%; p=0·0019) and 29 lowest-priced generics (–5·2%; p=0·0015); the median government procurement price for originator brands also decreased significantly (–10·9%; p=0·0004), whereas the decrease in median procurement price for lowest-priced generics was not significant (–4·9%; p=0·17). In the private sector, the median percentage decrease in price between 2010 and 2012 for 38 lowest-priced generics was 4·7% (IQR 6·3–13·2), compared with 7·9% (4·9–13·9) for 16 originator brands. Interpretation: Although inflation-adjusted medicine prices were numerically lower, there were concerning decreases in availability of lowest-priced generic medicines in both the public and private sectors in 2012 from already low availability in 2010. A long-term, stable, and consistent information system is needed to monitor effects of further implementation of the Chinese Essential Medicine Policy. Funding: The National Natural Science Fund (71103141/G0308), the China Medical Board Faculty Development Awards, the Fundamental Research Funds for the Central Universities (2011jdhz62), the Shaanxi Provincial Social Science Fund (10E066), and the Harvard Medical School Pharmaceutical Policy Research Fellowship.

Allocation and utilization of medicines in hospitals in urban China during the new health care reform

Availability, Use, and Affordability of Medicines in Urban China under Universal Health Coverage: an Empirical Study in Hangzhou and Baoji

An Analysis on Rational Use and Affordability of Medicine after the Implementation of National Essential Medicines Policy and Zero Mark-up Policy in Hangzhou, China

Intended and unintended impacts of the comprehensive reform of urban public hospitals: A mixed-method study in Hangzhou, China

A Survey of Availability, Price and Affordability of Essential Medicines from 2011 to 2016 in Chinese Secondary and Tertiary Hospitals

Allocation and Utilization of Essential Medicines at Primary Health Care Institutions

Investigation on the Utilization of Essential Medicines in 26 Rural Primary Medical Institutions from Poverty-stricken Areas of Huanggang City

Trends analysis for drug utilization in county public hospitals: a sample study of the pilot area of health care reform in China

Review on Pharmaceutical Pricing Reform of Urban Public Hospitals

Studv on the Current Situation of Allocation and Utilization of Major Medical Equipment in China and Relevant Policy Suggestions

Analysis on the Impacts of the Essential Medicines System on Primary Health Institutions in Shaanxi Province: Based on a Sample Survey of 4 Primary Health Institutions in 2 Counties

Impact of China's Public Hospital Reform on Healthcare Expenditures and Utilization: A Case Study in ZJ Province

Empirical Study on the Availability of Essential Medicines in Public Health and Medical Institutions of Shang-hai Qingpu District

Investigation and Survey of Essential Drugs Provision and Use in Primary Health Care Institutions from Some Areas in China

Access to Affordable Medicines after Health Reform: Evidence from Two Cross-Sectional Surveys in Shaanxi Province, Western China.

Evaluating the Price, Availability, and Affordability of Essential Medicines in Primary Healthcare Institutions: A Mixed Longitudinal and Cross-Sectional Study in Jiangsu, China

Evaluation of the Medication Rationality of National Essential Medicine System in Township Hospitals Imple-menting HealthⅪProject in Heilongjiang Province

The impacts and unintended consequences of the nationwide pricing reform for drugs and medical services in the urban public hospitals in China

The Impact of Sanming Healthcare Reform on Antibiotic Appropriate Use in County Hospitals in China

Impacts of essential medicine system on revenue structure:Evidence from township health cen-ter in Shanxi Province

Investigation on the Utilization of Essential Drugs in 23 Rural Primary Medical Institutions from Poverty-stricken Areas of Chongzuo City